Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry最新文献

{"title":"Analysis of Tolfenamic Acid using a Simple, Rapid, and Stability-indicating Validated HPLC Method.","authors":"Sadia Hafeez Kazi, Muhammad Ali Sheraz, Syed Ghulam Musharraf, Sofia Ahmed, Raheela Bano, Faraz Ul Haq, Zubair Anwar, Raahim Ali","doi":"10.2174/1871523022666230608094152","DOIUrl":"10.2174/1871523022666230608094152","url":null,"abstract":"<p><strong>Background: </strong>Tolfenamic acid (TA) belongs to the fenamates class of nonsteroidal anti-inflammatory drugs. Insufficient information is available regarding the availability of a reliable and validated stability-indicating method for the assay of TA.</p><p><strong>Objective: </strong>A relatively simple, rapid, accurate, precise, economical, robust, and stabilityindicating RP-HPLC method has been developed to determine TA in pure and tablet dosage forms.</p><p><strong>Methods: </strong>The method was validated according to the ICH guideline, and parameters like linearity, range, selectivity, accuracy, precision, robustness, specificity, and solution stability were determined. TLC and FTIR spectrometry were used to ascertain the purity of TA. The specificity was determined with known impurities and after performing forced degradation, while the robustness was established by Plackett-Burman's experimental design. The mobile phase used for the analysis was acetonitrile and water (90:10, v/v) at pH 2.5. The detection of the active drug was made at 280 nm using a C18 column (t_R = 4.3 min.). The method's applicability was also checked for the yellow polymorphic form of TA.</p><p><strong>Results: </strong>The results indicated that the method is highly accurate (99.39-100.80%), precise (<1.5% RSD), robust (<2% RSD), and statistically comparable to the British Pharmacopoeia method with better sensitivity and specificity.</p><p><strong>Conclusion: </strong>It was observed that the stress degradation studies do not affect the method's accuracy and specificity. Hence the proposed method can be used to assay TA and its tablet dosage form.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9598932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alkaloids Extract from <i>Linum usitatissimum</i> Attenuates 12-OTetradecanoylphorbol- 13-Acetate (TPA)-induced Inflammation and Oxidative Stress in Mouse Skin.","authors":"Mohamed Sofiane Merakeb,&nbsp;Noureddine Bribi,&nbsp;Riad Ferhat,&nbsp;Meriem Aziez,&nbsp;Betitera Yanat","doi":"10.2174/1871523022666221212121621","DOIUrl":"https://doi.org/10.2174/1871523022666221212121621","url":null,"abstract":"<p><strong>Background: </strong>In traditional medicine, Linum usitatissimum treats inflammatory, gastrointestinal, and cardiovascular diseases.</p><p><strong>Objectives: </strong>The present study aims to assess the anti-inflammatory and anti-oxidant effects of total alkaloid extract from Linum usitatissimum seeds (ALU) on the ear histological integrity and oxidant- antioxidant status in a mice model of a sub-chronic inflammation induced by multiapplication of TPA.</p><p><strong>Methods: </strong>Topical TPA treatment induced various inflammatory changes, including edema formation, epidermal thickness, and the excess production of reactive oxygen species. Tissue samples were used for the measurement of reduced glutathione (GSH) and nitric oxide (NO) levels and Myeloperoxidase (MPO) and Catalase (CAT) activities.</p><p><strong>Results: </strong>Oral administration of ALU (50, 100, and 200 mg/kg) produced anti-inflammatory and anti-oxidant effects. Also, ALU significantly reduced ear edema and inflammatory cell infiltration and restored the integrity of the ear.</p><p><strong>Conclusion: </strong>These findings suggest that the total alkaloid extract from Linum usitatissimum seeds presents significant anti-inflammatory and anti-oxidant effects on TPA-induced sub-chronic inflammation model in NMRI mice and can be used as an anti-inflammatory and anti-oxidant agent for the therapeutic management of inflammatory disorders.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9418594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome.","authors":"Castillo Tomas Augusto,&nbsp;María de la Paz Scribano Parada,&nbsp;Micaela Milagros Rossi,&nbsp;Franco Signorini,&nbsp;Ismael Fonseca,&nbsp;María del Carmen Baez","doi":"10.2174/1871523022666230223090714","DOIUrl":"https://doi.org/10.2174/1871523022666230223090714","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world. It is known that there is a pathogenic relation between liver damage and the inflammatory and oxidative environment present in Metabolic Syndrome (MS).</p><p><strong>Objective: </strong>To study the pharmacological action of atorvastatin and metformin in an experimental model of MS.</p><p><strong>Methods: </strong>We used 40 male rats (Wistar) divided into the following groups: Control (A) (n=8), induced MS (B) (n=8), MS + atorvastatin treatment (C)(n=8), MS + metformin treatment (D) (n=8) and MS + combined treatment (E) (n=8). MS was induced by administering 10% fructose in drinking water for 45 days. Atorvastatin 0.035 mg/day/rat, metformin 1.78 mg/day/rat, and a combination of both drugs were administered for 45 days. Metabolic, oxidative (nitric oxide, myeloperoxidase and superoxide dismutase) and inflammatory (fibrinogen) parameters were determined. Histological sections of liver were analyzed by light microscopy.</p><p><strong>Results: </strong>The glycemia, lipid profile and TG/HDL-C index were altered in MS group. After pharmacological treatment, metabolic parameters improve significantly in all treated groups. Inflammatory and oxidative stress biomarkers increase in MS. Treated groups showed an increase in NO bioavailability, no difference in MPO activity and an increase in fibrinogen. Atorvastatin showed a decrease in SOD while Metformin and combination treatment showed an increase in SOD compared to MS. In MS, we observed histological lesions consistent with NAFLD. However, after a combined treatment, we observed total regression of these lesions.</p><p><strong>Conclusion: </strong>Our results showed that there is an important synergy between atorvastatin and metformin in improving liver involvement in MS.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10866099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory Effects of First-line Anti-arthritic Drugs on T-cell Activation.","authors":"Nicholas Manolios,&nbsp;Guojiang Hou","doi":"10.2174/1871523022666230201144553","DOIUrl":"https://doi.org/10.2174/1871523022666230201144553","url":null,"abstract":"<p><strong>Aim: </strong>The in vitro effects of commonly used first-line anti-arthritic drugs on early stages of T-cell activation were examined.</p><p><strong>Methods: </strong>The 2B4.11 murine T cell hybridoma cell line recognizing pigeon cytochrome c (PCC) as the antigen was co-cultured with the histocompatible antigen presenting B cell hybridoma line LK35.2, PCC, and anti-arthritic drugs, including methotrexate, hydroxychloroquine, salazopyrine, cyclosporin, and leflunomide. After 16 hours of incubation, the supernatant was removed, and cytokines were assayed.</p><p><strong>Results: </strong>Anti-arthritic drugs inhibited the production of pro-inflammatory cytokines IL-2, IL-6, IFN-γ, GM-CSF, and TNF-α (Th1 cytokines) to a varying extent. Surprisingly, leflunomide, salazopyrine, prednisone and indomethacin as well as blocking Th1 cytokines, stimulated the production of the anti-inflammatory cytokine IL-10, a Th2 cytokine.</p><p><strong>Conclusion: </strong>Anti-arthritic medications can inhibit the production of pro-inflammatory cytokines and in some cases, incite a Th2 response that could potentially inhibit the progression of the immune response.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/5b/AIAAMC-21-188.PMC10226177.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9896917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marine Bioactive Phytoconstituents in Autoimmune Disorders: Role and Mechanism - A Review.","authors":"Dhanalekshmi Unnikrishnan Meenakshi,&nbsp;Gurpreet Kaur Narde,&nbsp;Alka Ahuja,&nbsp;Sammera Siddiqui","doi":"10.2174/1871523022666230731104529","DOIUrl":"https://doi.org/10.2174/1871523022666230731104529","url":null,"abstract":"<p><p>The significance of Autoimmune Disorders (Ads) is underscored by their chronic nature, high maintenance costs, and complexity affecting numerous organs and tissues. A more comprehensive approach to treating Ads is required across patient populations. A revolutionary area for obtaining an integrated therapeutic option is natural phytoconstituents. Diverse biomolecules with promising properties can be found in abundance in the marine environment. Many substances have been identified from sponges, bacteria, fungi, cyanobacteria, and algae that have been shown to have immunomodulatory activities and may be used as possible treatments for Ads. Marine-derived bioactive substances have been demonstrated to affect immunological responses and to be essential in immunotherapies. The amount of information about the specific effects of substances obtained from marine sources utilized as dietary supplements or for treating immune-related diseases is growing. This paper discusses many sources of potential marine metabolic chemicals, such as maritime flora and fauna. Numerous marine phytoconstituents have recently been isolated, described, and identified, and they are currently undergoing human usage studies. We have attempted to consolidate information concerning phytoconstituents from marine sources with anti-inflammatory and immunomodulatory properties in this review, and we have briefly explored their methods of action. In order to provide a baseline of knowledge for promoting marine flora-based phytoconstituents in the current context of increasing Ads incidence, deprived of the more affordable, safe, and effective medications to combat the terrible human disease, this paper reviews the works thus far conducted on this aspect.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10182220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucocorticoids, COVID-19 and Cryptococcosis.","authors":"Wanessa Maria Dos Santos, Alexandre Paula Rogerio","doi":"10.2174/1871523022666230912142540","DOIUrl":"10.2174/1871523022666230912142540","url":null,"abstract":"<p><p>Cryptococcus neoformans and C. gattii pneumonitis could persist asymptomatically for indefinite periods, resolve, or progress to symptomatic dissemination, mainly in immunocompromised individuals (e.g., treated with corticosteroids). The symptoms of COVID-19 may range from a self-limiting illness with general symptoms, such as fever, to more severe complications, such as pneumonitis. The glucocorticoids emerged as potential for treatment of COVID-19, mainly those patients who required ventilator therapy. However, although treatment with glucocorticoids has shown benefits in patients with COVID-19, they can be dangerous due to increased risk of coinfections and superinfections caused by opportunistic pathogens such as Cryptococcus ssp. Some patients with severe COVID-19 pneumonia treated with glucocorticoids developed cryptococcal infection and died. Therefore, immunomodulatory therapy could increase the susceptibility to acute infection or reactivation of Cryptococcus ssp in COVID-19 patients, and this could be complicated once pulmonary cryptococcosis has symptoms similar to COVID-19 becomes difficult to distinguish between the two disease states and treatment.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10221667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Update on Herbal Products for the Management of Inflammatory Bowel Disease.","authors":"Himanshu Arya,&nbsp;Rameshwar Dass,&nbsp;Bhawna Chopra,&nbsp;Priyanka Kriplani,&nbsp;Geeta Deswal,&nbsp;Ajmer Singh Grewal,&nbsp;Ashwani K Dhingra,&nbsp;Suresh Kumar","doi":"10.2174/1871523022666230727094250","DOIUrl":"https://doi.org/10.2174/1871523022666230727094250","url":null,"abstract":"<p><p>Inflammatory Bowel Disease (IBD), including Ulcerative Colitis (UC) and Crohn's Disease (CD), is a continuously increasing healthcare problem mainly characterized by chronic relapsing intestinal inflammation. The common symptoms of UC and CD include inflammation, diarrhea, abdominal pain, bleeding, and weight loss. IBD is generally caused by an interaction between genetic and environmental or microbial factors that influence the body's immune response and is responsible for digestive disorders and inflammation of the intestinal tract. However, a complete understanding of the pathophysiology and work-up of IBD is necessary to ensure appropriate treatment for the management of this complex disease. This review enlightens herbal therapeutics and drug delivery systems for the management of IBD, and thus provides new insights into this field and facilitates access to new treatments.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10199399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Predictors of Hepatorenal Syndrome Development in HCV Cirrhotic Ascitic Egyptian Patients with Spontaneous Bacterial Peritonitis.","authors":"Shimaa Mahmoud El Sharawy,&nbsp;Mahmoud Zaki Elkadeem,&nbsp;Ibrahim Fathi Amer","doi":"10.2174/1871523022666230613160225","DOIUrl":"https://doi.org/10.2174/1871523022666230613160225","url":null,"abstract":"<p><strong>Background & aim: </strong>Spontaneous bacterial peritonitis is considered a precipitating factor for renal impairment in patients with liver cirrhosis. No specific study addressing this problem has been reported. This study aimed to detect the incidence and predictive factors of hepatorenal syndrome in these patients.</p><p><strong>Materials and methods: </strong>This study enrolled 121 hepatic cirrhotic patients with spontaneous bacterial peritonitis. History taking, clinical examination, and laboratory investigations including ascitic fluid analysis were carried out. Kidney function tests were repeated 3 days after the initiation of treatment. Patients were divided into 2 groups after one week of treatment during the follow-up period: Group I: patients without hepatorenal syndrome, and Group II: patients with hepatorenal syndrome. Multivariate analysis was performed to determine independent predictors of hepatorenal syndrome development.</p><p><strong>Results: </strong>A total of 30 patients (24.8%) developed hepatorenal syndrome. Patients with hepatorenal syndrome had significantly lower sodium and albumin levels as well as higher creatinine, bilirubin, Child-Turcotte-Pugh score, portal vein diameter, Model for End-Stage Liver Disease score. Higher percentage of them had a history of recurrent spontaneous bacterial peritonitis and multiple therapeutic paracentesis of ascites. Multivariate analysis detected that serum bilirubin, Model for End-Stage Liver Disease-Sodium, and portal vein diameter were significant predictors of hepatorenal syndrome. Cutoff values were determined as 3.3 mg/dl for bilirubin, 15.9 mm for portal vein diameter, and 26 for Model for End-Stage Liver Disease-Sodium.</p><p><strong>Conclusion: </strong>Hepatorenal syndrome is a common complication of spontaneous bacterial peritonitis. In our study, high serum bilirubin, Model for End-Stage Liver Disease-Sodium, and portal vein diameter are predictors of the development of hepatorenal syndrome in patients with spontaneous bacterial peritonitis.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quercetin and Its Role in Reducing the Expression of Pro-inflammatory Cytokines in Osteoarthritis.","authors":"Elahe Aleebrahim-Dehkordi,&nbsp;Faezeh Soveyzi,&nbsp;Ali Sam Arian,&nbsp;Neda Faal Hamedanchi,&nbsp;Ayda Hasanpour-Dehkordi,&nbsp;Mahmoud Rafieian-Kopaei","doi":"10.2174/1871523022666221213155905","DOIUrl":"https://doi.org/10.2174/1871523022666221213155905","url":null,"abstract":"<p><p>Osteoarthritis is the most common human joint disease in the world. It is also one of the most common skeletal muscle defects, destructive joint changes, and the leading cause of disability and reduced quality of life. Destructive changes in inflammatory joints are associated with a range of biochemical events, including the overproduction of inflammatory cytokines. Cytokines are protein compounds that play an essential role in causing and regulating inflammation. A balance between pro-inflammatory and anti-inflammatory cytokines is crucial in maintaining a stable body. In some inflammatory diseases, including osteoarthritis, the balance between these compounds is disturbed, and the balance shifts to pre-inflammatory cytokines. For this reason, researchers today are trying to find an effective way to reduce inflammation and treat osteoarthritis by using certain compounds. Current treatments for osteoarthritis, including nonsteroidal antiinflammatory drugs, glucocorticoids, and hyaluronic acid, are mainly based on reducing pain and inflammation. However, they have limited effects in controlling symptoms and improving the patient's quality of life. Also, due to the high level of side effects, synthetic drugs have led to the identification of compounds of natural origin to give patients a chance to use painkillers and antiinflammatory drugs with fewer side effects. This review study aimed to present the role of quercetin as a natural compound in reducing the expression of pro-inflammatory cytokines in osteoarthritis. This study also discusses the relationship between inflammation and cartilage destruction and other inflammation-related factors caused by cytokines.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9106322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Moisturiser Improves DNCB-induced Atopic Dermatitis-like Symptoms and Restores Skin Barrier Function in BALB/c Mice.","authors":"Christelle Foucher,&nbsp;Jean-François Bisson,&nbsp;Martine Guy,&nbsp;Hao Trong Nguyen,&nbsp;Sophie Hidalgo,&nbsp;Julie Colin,&nbsp;Tu Nguyen Anh Tran,&nbsp;Thao Thi Phuong Vu","doi":"10.2174/1871523022666230529150043","DOIUrl":"https://doi.org/10.2174/1871523022666230529150043","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic, inflammatory skin disorder with eczematous and pruritic lesions. Topical moisturisers and either topical corticosteroids or calcineurin inhibitors are usually recommended. Restoring the skin barrier function alleviates AD symptoms.</p><p><strong>Objective: </strong>To evaluate the efficacy of a new moisturiser compared to commercially available products in an AD murine model.</p><p><strong>Methods: </strong>Experimental AD was induced with topical applications of 2,4-DiNitroChloroBenzene (DNCB) on the shaved back skin of BALB/c mice from Day 1 to Day 38. Mice were randomized to either Vehicle/-, DNCB/-, or DNCB/Eczekalm (test product), DNCB/Atopiclair®, or DNCB/Lipikar (reference products) groups. Once daily application of either Eczekalm or Atopiclair® or Lipikar on the AD lesion was performed from Day 32 to Day 38. The AD severity index (ADSI) and animal behaviour were monitored throughout the study. The trans-epidermal water loss (TEWL) was measured on the sacrifice day (Day 39).</p><p><strong>Results: </strong>At Day39, ADSI in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower by -70%, -68%, and -57%, respectively, as compared to DNCB/- (p < 0.001). No sign of erythema was observed in the DNCB/Eczekalm group. Mean scores of skin oedema, excoriation, and dryness in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower than in the DNCB/-. No significant difference was observed between DNCB/Eczekalm and DNCB/Lipikar groups. Mean TEWL in DNCB/Eczekalm group was significantly lower than the ones of DNCB/Atopiclair® (-43%, p < 0.001) and DNCB/Lipikar (-15%, p < 0.05).</p><p><strong>Conclusion: </strong>Eczekalm treatment significantly reduced the inflammatory effects due to AD and itching episodes and restored the skin barrier function.</p>","PeriodicalId":35423,"journal":{"name":"Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10141704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}